Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Key Takeaways Phase 2 retatrutide reduced mean systolic blood pressure by approximately 7-8 mmHg at top doses over 48 weeks Diastolic blood pressure dropped by approximately 2-4 mmHg Placebo arm BP changes were minimal, so the active-versus-placebo gap is real and meaningful The effect tracks with weight loss, suggesting most of the benefit is downstream of weight reduction rather than a direct vascular drug effect Patients on antihypertensive medications often need dose reductions as weight loss progresses to avoid excessive BP drops Direct answer Yes
Cross-class GIP functional potency retatrutide GIPR EC50 0.0643 nM (Coskun 2022) vs tirzepatide GIPR EC50 1.01 nM (Willard FS, et al
Whether retatrutide or one of todays proven medications is the better fit for you is exactly the kind of question our providers answer at Body Works in Franklin, TN and Nolensville, TN
Stability Notes: Exposure to temperatures above 25C or repeated freeze-thaw cycles may compromise peptide integrity
US$ 20.58
US$ 27.66
US$ 26.35
US$ 26.86
US$ 20.63
US$ 20.17
US$ 27.17
US$ 28.80
